Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant differences in immunohistochemical marker expression

详细信息    查看全文

• 作者：Fisnik Kurshumliu (3) (6)
  Lumturije Gashi-Luci (3)
  Shahin Kadare (4)
  Mehdi Alimehmeti (5)
  Ugur Gozalan (6)
  
  3. Institute of Anatomic Pathology ; University Clinical Center ; Medical School ; University of Pristina ; Pristina ; Kosovo
  6. American Hospital Kosova ; Pristina ; Kosovo
  4. Laboratori Diagnostik Morfopatologjik ; Tirana ; Albania
  5. Sh毛rbimi i Anatomis毛Patologjike ; Qendra Spitalore Universitare N毛naTerez毛 ; Tirana ; Albania
  
• 关键词：Breast cancer ; Nottingham Prognostic Index ; Immunohistochemistry
• 刊名：World Journal of Surgical Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：12
• 期：1
• 全文大小：395 KB
• 参考文献：1. Rakha, EA, Soria, D, Green, AR, Lemetre, C, Powe, DG, Nolan, CC, Garibaldi, JM, Ball, G, Ellis, IO (2014) Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer 110: pp. 1688-1697 CrossRef
  2. Green, AR, Powe, DG, Rakha, EA, Soria, D, Lemetre, C, Nolan, CC, Barros, FF, Macmillan, RD, Garibaldi, JM, Ball, GR, Ellis, IO (2013) Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Br J Cancer 109: pp. 1886-1894 CrossRef
  3. Soria, D, Garibaldi, JM, Ambrogi, F, Green, AR, Powe, D, Rakha, E, Macmillan, RD, Blamey, RW, Ball, G, Lisboa, PJ, Etchells, TA, Boracchi, P, Biganzoli, E, Ellis, IO (2010) A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 40: pp. 318-330 CrossRef
  4. Rakha, EA, Reis-Filho, JS, Baehner, F, Dabbs, DJ, Decker, T, Eusebi, V, Fox, SB, Ichihara, S, Jacquemier, J, Lakhani, SR, Palacios, J, Richardson, AL, Schnitt, SJ, Schmitt, FC, Tan, PH, Tse, GM, Badve, S, Ellis, IO (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12: pp. 207
  5. Sundquist, M, Thorstenson, S, Brudin, L, Nordenskj枚ld, B (1999) Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 53: pp. 1-8 CrossRef
  6. Perou, CM, S酶rlie, T, Eisen, MB, van de Rijn, M, Jeffrey, SS, Rees, CA, Pollack, JR, Ross, DT, Ross, DT, Johnsen, H, Akslen, LA, Fluge, O, Pergamenschikov, A, Williams, C, Zhu, SX, L酶nning, PE, B酶rresen-Dale, AL, Brown, PO, Botstein, D (2000) Molecular portraits of human breast tumours. Nature 406: pp. 747-752 CrossRef
  7. S酶rlie, T, Perou, CM, Tibshirani, R, Aas, T, Geisler, S, Johnsen, H, Hastie, T, Eisen, MB, van de Rijn, M, Jeffrey, SS, Thorsen, T, Quist, H, Matese, JC, Brown, PO, Botstein, D, L酶nning, PE, B酶rresen-Dale, AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: pp. 10869-10874 CrossRef
  8. Sotiriou, C, Neo, SY, McShane, LM, Korn, EL, Long, PM, Jazaeri, A, Martiat, P, Fox, SB, Harris, AL, Liu, ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: pp. 10393-10398 CrossRef
  9. Chen, C, Dhanda, R, Tseng, W-Y, Forsyth, M, Patt, DA (2013) Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract Am Soc Clin Oncol 9: pp. 182-187
  10. De Boer, RH, Baker, C, Speakman, D, Chao, CY, Yoshizawa, C, Mann, GB (2013) The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Med J Aust 199: pp. 205-208 CrossRef
  11. Carlson, JJ, Roth, JA (2013) The impact of the OncotypeDx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 141: pp. 13-22 CrossRef
  12. Geradts, J, Bean, SM, Bentley, RC, Barry, WT (2010) The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 28: pp. 969-977 CrossRef
  13. DeFrank, JT, Salz, T, Reeder-Hayes, K, Brewer, NT (2013) Who gets genomic testing for breast cancer recurrence risk?. Public Health Genomics 16: pp. 215-222 CrossRef
  14. Harbeck, N, Sotlar, K, Wuerstlein, R, Doisneau-Sixou, S (2014) Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat Rev 40: pp. 434-444 CrossRef
  15. Galea, MH, Blamey, RW, Elston, CE, Ellis, IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: pp. 207-219 CrossRef
  16. Rakha, EA, El-Sayed, ME, Lee, AHS, Elston, CW, Grainge, MJ, Hodi, Z, Blamey, RW, Ellis, IO (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26: pp. 3153-3158 CrossRef
  17. Blamey, RW, Ellis, IO, Pinder, SE, Lee, AHS, Macmillan, RD, Morgan, DA, Robertson, JF, Mitchell, MJ, Ball, GR, Haybittle, JL, Elston, CW (2007) Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 19901999. Eur J Cancer 43: pp. 1548-1555 CrossRef
  18. Hammond, MEH, Hayes, DF, Dowsett, M, Allred, DC, Hagerty, KL, Badve, S, Fitzgibbons, PL, Francis, G, Goldstein, NS, Hayes, M, Hicks, DG, Lester, S, Love, R, Mangu, PB, McShane, L, Miller, K, Osborne, CK, Paik, S, Perlmutter, J, Rhodes, A, Sasano, H, Schwartz, JN, Sweep, FC, Taube, S, Torlakovic, EE, Valenstein, P, Viale, G, Visscher, D, Wheeler, T, Williams, RB (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med 134: pp. 907-922
  19. Wolff, AC, Hammond, ME, Hicks, DG, Dowsett, M, McShane, LM, Allison, KH, Allred, DC, Bartlett, JM, Bilous, M, Fitzgibbons, P, Hanna, W, Jenkins, RB, Mangu, PB, Paik, S, Perez, EA, Press, MF, Spears, PA, Vance, GH, Viale, G, Hayes, DF (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 31: pp. 3997-4013 CrossRef
  20. Goldhirsch, A, Winer, EP, Coates, AS, Gelber, RD, Piccart-Gebhart, M, Th眉rlimann, B, Senn, HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24: pp. 2206-2223 CrossRef
  21. Callagy, GM, Pharoah, PD, Pinder, SE, Hsu, FD, Nielsen, TO, Ragaz, J, Ellis, IO, Huntsman, D, Caldas, C (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12: pp. 2468-2475 CrossRef
  22. Yamashita, H, Toyama, T, Nishio, M, Ando, Y, Hamaguchi, M, Zhang, Z, Kobayashi, S, Fujii, Y, Iwase, H (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8: pp. R48 CrossRef
  23. Hwang, KT, Woo, JW, Shin, HC, Kim, HS, Ahn, SK, Moon, HG, Han, W, Park, IA, Noh, DY (2012) Prognostic influence of BCL2 expression in breast cancer. Int J Cancer 131: pp. 1109-1119 CrossRef
  24. Zhang, GJ, Kimijima, I, Tsuchiya, A, Abe, R (1998) The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep 5: pp. 1211-1216
  25. Miyashita, T, Krajewski, S, Krajewska, M, Wang, HG, Lin, HK, Liebermann, DA, Hoffman, B, Reed, JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: pp. 1799-1805
  26. Haldar, S, Negrini, M, Monne, M, Sabbioni, S, Croce, CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: pp. 2095-2097
  27. Alsabeh, R, Wilson, CS, Ahn, CW, Vasef, MA, Battifora, H (1995) Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol 9: pp. 439-444
  28. Vogelstein, B, Kinzler, KW (2001) Achilles鈥?heel of cancer?. Nature 412: pp. 865-866 CrossRef
  
• 刊物主题：Surgical Oncology;
• 出版者：BioMed Central
• ISSN：1477-7819

文摘

Background Prognosis and treatment of patients with breast carcinoma of no special type (NST) is dependent on a few established parameters, such as tumor size, histological grade, lymph node stage, expression of estrogen receptor, progesterone receptor, and HER-2/neu, and proliferation index. The original Nottingham Prognostic Index (NPI) employs a three-tiered classification system that stratifies patients with breast cancer into good, moderate, and poor prognostic groups. The aim of our study was to use robust immunohistochemical methodology for determination of ER, PR, HER-2/neu, Ki-67, p53, and Bcl-2, and to observe differences in the expression of these markers when patients are stratified according to the original, three-tiered Nottingham Prognostic Index. Methods Paraffin blocks from 120 patients diagnosed with breast carcinoma, NST, were retrieved from our archive. Cases included in the study were female patients previously treated with modified radical mastectomy and axillary dissection. Results Our study demonstrates that expression of markers of good prognosis, such as ER, PR, and Bcl-2, is seen with higher frequency in good and moderate NPI groups. In contrast, overexpression of HER-2/neu, a marker of adverse prognosis, is more frequent in moderate and poor NPI groups. High proliferation index, as measured by Ki-67, is seen in moderate and poor NPI groups, whereas low proliferation index is seen in good NPI groups. Conclusions These data confirm that the original, three-tiered NPI statistically correlates with the expression of prognostic immunohistochemical markers in breast carcinoma NST.